Hughes Watler - Rapid Therapeutic CFO Director
| RTSL Stock | USD 0 0.00 0.00% |
Insider
Hughes Watler is CFO Director of Rapid Therapeutic Science
| Age | 74 |
| Phone | 800 497 6059 |
| Web | https://www.rtslco.com |
Rapid Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.554) % which means that it has lost $0.554 on every $100 spent on assets. This is way below average. Rapid Therapeutic's management efficiency ratios could be used to measure how well Rapid Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | INSIDER Age | ||
| Richard Ginn | Tenon Medical | 58 | |
Management Performance
| Return On Asset | -0.55 |
Rapid Therapeutic Science Leadership Team
Elected by the shareholders, the Rapid Therapeutic's board of directors comprises two types of representatives: Rapid Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rapid. The board's role is to monitor Rapid Therapeutic's management team and ensure that shareholders' interests are well served. Rapid Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rapid Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Donal Schmidt, CEO Pres | ||
| Duane Drinkwine, Chief Officer | ||
| Hughes Watler, CFO Director | ||
| Sean Berrier, VP | ||
| Frank Gill, Chief Technician | ||
| Ryan Johnson, VP Marketing |
Rapid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rapid Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.55 | |||
| Current Valuation | 13.08 M | |||
| Shares Outstanding | 7.75 M | |||
| Shares Owned By Insiders | 66.33 % | |||
| Price To Book | 136.70 X | |||
| Price To Sales | 193,667 X | |||
| Revenue | 534 | |||
| Gross Profit | 334 | |||
| EBITDA | (1.48 M) | |||
| Net Income | (2.87 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.